Skip to content
20 November · 06:30 UTCFollow AstraZeneca by emailFollow

AZN · story · 20 November

Sone-Ve, AstraZeneca's gastric cancer drug, receives priority review from the FDA

AstraZeneca · 13 headlines from 13 outlets, on 20 November 2026.

The story

+9.4strongly positive
Headlines13
Outlets13
Days120 November

The FDA accepted the BLA for sonesitatug vedotin with priority review for CLDN18.2-positive gastric cancers.

The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

How each outlet covered it · 13 outlets

The 10 outlets with the most impact on the tone

Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.

Source: MarketFrame news analysis

The 10 outlets with the most impact on the tone. Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone. Source: MarketFrame news analysis
outletAverage tone
grafa.com10.0
Seeking Alpha9.7
London South East9.5
StreetInsider9.5
Investing.com9.5
Yahoo Finance9.5
FirstWord Pharma9.3
Securities.io9.3
TradingView9.3
AD HOC NEWS9.3
OutletHeadlinesAverage tone
grafa.com1+10.0
Seeking Alpha1+9.7
London South East1+9.5
StreetInsider1+9.5
Investing.com1+9.5
Yahoo Finance1+9.5
FirstWord Pharma1+9.3
Securities.io1+9.3
TradingView1+9.3
AD HOC NEWS1+9.3
All 13 outlets
OutletHeadlinesAverage tone
The Pharma Letter1+9.2
TipRanks1+9.2
GenomeWeb1+8.3

One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Day by day · 1 day, strongest headlines first

Friday 20 November 202613 headlines · The FDA accepted the BLA for sonesitatug vedotin with priority review for CLDN18.2-positive gastric cancers.+9.4
ToneWhat the article reported, and why it scored that waySource
+10.0Regulator fast-tracks cancer drug backed by strong survival benefit.grafa.com (opens the article) ↗
+9.7Accelerated regulatory review granted for gastric cancer therapy.Seeking Alpha (opens the article) ↗
+9.5US regulator expedites review of cancer drug.London South East (opens the article) ↗
+9.5US regulator gives faster review to gastric cancer candidate.StreetInsider (opens the article) ↗
+9.5Gastric cancer medicine receives accelerated US regulatory review.Investing.com (opens the article) ↗
+9.5Official announcement of accelerated US review for gastric cancer drug.Yahoo Finance (opens the article) ↗
+9.3Quick regulatory review for targeted gastric cancer treatment.FirstWord Pharma (opens the article) ↗
+9.3Gastric cancer drug obtains accelerated US regulatory review.Securities.io (opens the article) ↗
5 more headlines that day
ToneWhat the article reported, and why it scored that waySource
+9.3Company announces accelerated US review of its application.TradingView (opens the article) ↗
+9.3Share-focused coverage of accelerated regulatory review for cancer drug.AD HOC NEWS (opens the article) ↗
+9.2Licence application accepted for expedited US assessment.The Pharma Letter (opens the article) ↗
+9.2Licence application accepted with accelerated review status.TipRanks (opens the article) ↗
+8.3Company pursuing American approval for gastric cancer treatment.GenomeWeb (opens the article) ↗

Follow by email

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 20 November · 852 headlines · 87 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt